We provide a full research cycle for rare diseases, starting from preclinical studies through to the final clinical report. At the preclinical stage, special attention is given to safety, quality, and efficacy of medicines in accordance with Russian legislation and international standards. We conduct studies of reproduced and generic drugs with consideration of specific bioequivalence requirements, develop study designs for novel molecules including innovative therapeutic approaches, and organize specialized projects for biological medicines. All stages are supported by thorough analytics, monitoring, quality control, and reporting to regulatory authorities.

Clinical trials of phases I–IV are designed with the specifics of rare diseases in mind, where the limited number of patients requires particularly careful organization and personalized support of each participant. Our team ensures the development of study programs and protocols, interaction with ethics committees and the Ministry of Health, data management in dedicated EDC systems, as well as logistics, storage, and accountability of investigational products. Compliance is a core part of our approach: standard operating procedures, staff qualification, information security, and corporate policies guarantee the highest level of reliability.
With experience in more than 20 international projects and a strong network of leading national medical research centers and regional clinics, we build the scientific foundation for further drug registration and ensure alignment with the highest quality standards